Abbreviations: SMZL, splenic marginal zone lymphoma; CVP, cyclophosphamide, vincristine and prednisone; CIT, chemo immuno therapy; SR, splenic radiotherapy OpinionSplenic marginal zone lymphoma (SMZL) is a rare malignant condition of B cells. It usually manifests with massive splenomegaly, and has frequent bone marrow and peripheral blood involvement.1 It amounts to 5% of non-Hodgkin's lymphomas and less than 1-2% of leukemias derived from low-grade lymphomas. SMZL, however, can be found in up to 25% of lymphomas diagnosed after a splenectomy. Its course is indolent, and its symptoms are vague and related to the discomfort caused by splenomegaly and cytopenia secondary to